Pluvicto Prostate Cancer Trial: Phase III Results

By João L. Carapinha

June 3, 2025

Novartis recently announced the topline results from the Phase III Pluvicto prostate cancer trial. The addition of Pluvictoâ„¢ (lutetium (177Lu) vipivotide tetraxetan) to standard hormone therapy significantly improved radiographic progression-free ...

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.